Mylan, Teva Settle Over Generic Provigil Market Rights

Law360, New York (June 8, 2012, 2:10 PM EDT) -- Mylan Inc. has settled its dispute with Teva Pharmaceuticals USA Inc. concerning its suit against the U.S. Food and Drug Administration over allegations that Teva and subsidiary Cephalon Inc. worked to stymie generic competition of the sleep disorder drug Provigil, Mylan said Friday.

Mylan originally sued the FDA on April 5 seeking to derail the marketing exclusivity period the agency awarded to Cephalon based on patent certifications Mylan says are invalid.

The settlement concerns Mylan subsidiary Mylan Pharmaceuticals Inc.’s abbreviated new drug application for 100-mg and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.